Personal Account

Weekly Market Recap: Jersey Mike's, Reformation, Apnimed Debut

Three IPOs, three different outcomes — plus an Anthropic roadshow update and next week's biotech wave

Three IPOs debuted this week with three different outcomes, Anthropic's roadshow moved a step closer to a public listing, and next week brings a wave of biotech debuts. Here's what happened in the IPO and pre-IPO market for the week of July 27–31, 2026.

This Week's Debuts

  • Jersey Mike's Subs (NYSE: JMKE) — priced at $23, raised nearly $1 billion at a ~$7.3B valuation, then fell about 6% on its first trading day. One of the largest restaurant IPOs on record, but a reminder that brand recognition doesn't guarantee aftermarket demand.
  • Reformation (NYSE: REF) — the sustainable womenswear brand priced at $15 per share, raising $210.9 million at an $886 million valuation. Shares closed essentially flat on debut day (July 30), with the CEO saying the company is "ready to scale."
  • Apnimed (Nasdaq: APMD) — the Phase 3 pharmaceutical company (developing an oral treatment for obstructive sleep apnea) priced at $16, the top of its range, upsizing to 12 million shares to raise $192 million.

Fact vs. estimate: pricing, share counts and first-day closes above are confirmed market data. Read-throughs on "why" a stock traded up, down or flat are analysis, not fact.

Anthropic: Roadshow Moves Forward

Banks — reportedly including Morgan Stanley, Goldman Sachs and JPMorgan — continued investor meetings this month for what could be a Nasdaq listing as early as October 2026, at a $965 billion valuation set in Anthropic's May Series H round. Nothing is official until the S-1 is public, but the roadshow itself is a concrete step most confidential IPO candidates don't reach until a listing is genuinely close.

What's Ahead Next Week

A cluster of biotech IPOs is set to price August 5–6: Attovia Therapeutics (Nasdaq: ATTO, targeting $15–$17, ~$200M) and Braveheart Bio (Nasdaq: BRVE, targeting $15–$17, ~$300M), alongside Vogenx (Nasdaq: VOGX, targeting $11–$13, ~$75M) — together aiming to raise over $500 million. Multiple biotechs pricing in the same window usually signals bankers see a receptive window for the sector; it's also a window that can close quickly if the first movers price or trade poorly. Full details in our IPO Calendar.

Why It Matters for Pre-IPO and Tokenized Equity Investors

This week's split result — one debut down, one flat, one priced at the top of its range — is a useful reminder that public-market reception varies by sector and deal structure, not just by brand strength or pre-IPO hype. Watching how debuts actually trade, not just how they're marketed, is a better read on where investor appetite currently sits.

This material is for informational purposes only and does not constitute individual investment advice.

Sources

Please fill out the form and receive a free consultation from our investment expert

Spend 5 minutes to create your account and begin investing right after the registration


2022 © All rights reserved

You can always come to our office to discuss any questions with our manager

Dubai

Sharjah Media City, Sharjah, UAE

USA

500 Delaware ave,
STE 1 #1960 Wilmington, DE, USA

Czech Republic

Czech Republic, Prague, Bilkova 855/19

The investment opportunities posted on this website's Pre-IPO section are private placements of securities that are not traded on the open market, subject to the ownership period requirements, and intended for investors who do not require liquid investments. Investments in private companies may be considered speculative, involving high risk, including the significant loss of investment risk. Investors must be able to afford to lose all their investments.